Anticoagulants contributing to haematuria referral to secondary care and their outcomes
BAUS ePoster online library. Naathan H. 06/21/21; 319125; p8-7
Disclosure(s): Nothing to disclose
Habillan Naathan
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Introduction:
The purpose of our study is to find out how many patients, referred onto the haematuria pathway in secondary care, are on anticoagulants and is there any difference in urothelial cancer detection rates among these.
Patients and Methods:
We reviewed 825 patients referred to haematuria clinic; male to female ratio 2.1:1, mean age 70.8 years, VH-585 (70.1%), NVH-240 (29.9%). All patients were categorised into groups of: anti-platelets, warfarin, NOACs, dual anti-platelet therapy (DAPT), aspirin and patients not on anticoagulants. Patients were investigated as per protocol: for NVH-flexible cystoscopy, US KUB and CTU if history of risk factors, and for VH-flexible cystoscopy and CTU. Patients with abnormal findings on flexible cystoscopy were further investigated with rigid cystoscopy +/- biopsies.
Results:
24.4% of haematuria clinical referrals were on anticoagulants (excluding aspirin), mean age 72.75 years (NVH- 22%; VH-78%). Mean age was 73.9 years and 62.8 years in aspirin and not on anticoagulant groups, respectively. Among anticoagulants, NOACs made up 14.1% of all referrals, followed by anti-platelets-7.9%, warfarin-4.7%, DAPT-2.7% and enoxaparin-0.12%. Aspirin contributed to 13% of all referrals. Urothelial TCC was found as: warfarin -4/39 (10.2%); anti-platelets-6/65 (9.2%); DAPT-2/22 (9%); aspirin-10/108 (9.2%) and in NOACs 8/117(6.8%).
Conclusion:
Patients on anticoagulants present late when compared to patients not on anticoagulants. The NOACs was the most common group that contributed to haematuria pathway. Urothelial tumours were most commonly found in patients on warfarin. The prevalence of TCC in patients not on anti-coagulant is 5.8%.
The purpose of our study is to find out how many patients, referred onto the haematuria pathway in secondary care, are on anticoagulants and is there any difference in urothelial cancer detection rates among these.
Patients and Methods:
We reviewed 825 patients referred to haematuria clinic; male to female ratio 2.1:1, mean age 70.8 years, VH-585 (70.1%), NVH-240 (29.9%). All patients were categorised into groups of: anti-platelets, warfarin, NOACs, dual anti-platelet therapy (DAPT), aspirin and patients not on anticoagulants. Patients were investigated as per protocol: for NVH-flexible cystoscopy, US KUB and CTU if history of risk factors, and for VH-flexible cystoscopy and CTU. Patients with abnormal findings on flexible cystoscopy were further investigated with rigid cystoscopy +/- biopsies.
Results:
24.4% of haematuria clinical referrals were on anticoagulants (excluding aspirin), mean age 72.75 years (NVH- 22%; VH-78%). Mean age was 73.9 years and 62.8 years in aspirin and not on anticoagulant groups, respectively. Among anticoagulants, NOACs made up 14.1% of all referrals, followed by anti-platelets-7.9%, warfarin-4.7%, DAPT-2.7% and enoxaparin-0.12%. Aspirin contributed to 13% of all referrals. Urothelial TCC was found as: warfarin -4/39 (10.2%); anti-platelets-6/65 (9.2%); DAPT-2/22 (9%); aspirin-10/108 (9.2%) and in NOACs 8/117(6.8%).
Conclusion:
Patients on anticoagulants present late when compared to patients not on anticoagulants. The NOACs was the most common group that contributed to haematuria pathway. Urothelial tumours were most commonly found in patients on warfarin. The prevalence of TCC in patients not on anti-coagulant is 5.8%.
Introduction:
The purpose of our study is to find out how many patients, referred onto the haematuria pathway in secondary care, are on anticoagulants and is there any difference in urothelial cancer detection rates among these.
Patients and Methods:
We reviewed 825 patients referred to haematuria clinic; male to female ratio 2.1:1, mean age 70.8 years, VH-585 (70.1%), NVH-240 (29.9%). All patients were categorised into groups of: anti-platelets, warfarin, NOACs, dual anti-platelet therapy (DAPT), aspirin and patients not on anticoagulants. Patients were investigated as per protocol: for NVH-flexible cystoscopy, US KUB and CTU if history of risk factors, and for VH-flexible cystoscopy and CTU. Patients with abnormal findings on flexible cystoscopy were further investigated with rigid cystoscopy +/- biopsies.
Results:
24.4% of haematuria clinical referrals were on anticoagulants (excluding aspirin), mean age 72.75 years (NVH- 22%; VH-78%). Mean age was 73.9 years and 62.8 years in aspirin and not on anticoagulant groups, respectively. Among anticoagulants, NOACs made up 14.1% of all referrals, followed by anti-platelets-7.9%, warfarin-4.7%, DAPT-2.7% and enoxaparin-0.12%. Aspirin contributed to 13% of all referrals. Urothelial TCC was found as: warfarin -4/39 (10.2%); anti-platelets-6/65 (9.2%); DAPT-2/22 (9%); aspirin-10/108 (9.2%) and in NOACs 8/117(6.8%).
Conclusion:
Patients on anticoagulants present late when compared to patients not on anticoagulants. The NOACs was the most common group that contributed to haematuria pathway. Urothelial tumours were most commonly found in patients on warfarin. The prevalence of TCC in patients not on anti-coagulant is 5.8%.
The purpose of our study is to find out how many patients, referred onto the haematuria pathway in secondary care, are on anticoagulants and is there any difference in urothelial cancer detection rates among these.
Patients and Methods:
We reviewed 825 patients referred to haematuria clinic; male to female ratio 2.1:1, mean age 70.8 years, VH-585 (70.1%), NVH-240 (29.9%). All patients were categorised into groups of: anti-platelets, warfarin, NOACs, dual anti-platelet therapy (DAPT), aspirin and patients not on anticoagulants. Patients were investigated as per protocol: for NVH-flexible cystoscopy, US KUB and CTU if history of risk factors, and for VH-flexible cystoscopy and CTU. Patients with abnormal findings on flexible cystoscopy were further investigated with rigid cystoscopy +/- biopsies.
Results:
24.4% of haematuria clinical referrals were on anticoagulants (excluding aspirin), mean age 72.75 years (NVH- 22%; VH-78%). Mean age was 73.9 years and 62.8 years in aspirin and not on anticoagulant groups, respectively. Among anticoagulants, NOACs made up 14.1% of all referrals, followed by anti-platelets-7.9%, warfarin-4.7%, DAPT-2.7% and enoxaparin-0.12%. Aspirin contributed to 13% of all referrals. Urothelial TCC was found as: warfarin -4/39 (10.2%); anti-platelets-6/65 (9.2%); DAPT-2/22 (9%); aspirin-10/108 (9.2%) and in NOACs 8/117(6.8%).
Conclusion:
Patients on anticoagulants present late when compared to patients not on anticoagulants. The NOACs was the most common group that contributed to haematuria pathway. Urothelial tumours were most commonly found in patients on warfarin. The prevalence of TCC in patients not on anti-coagulant is 5.8%.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}